Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a sell rating to a hold rating in a report published on Sunday morning.

A number of other equities research analysts also recently weighed in on ATNM. HC Wainwright restated a buy rating and set a $50.00 target price on shares of Actinium Pharmaceuticals in a research report on Monday, April 29th. Maxim Group raised their target price on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a buy rating in a research note on Tuesday, March 19th. Finally, Cantor Fitzgerald reissued an overweight rating and set a $21.00 price target on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 30th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $25.72.

Actinium Pharmaceuticals Price Performance

Shares of ATNM stock opened at $8.71 on Friday. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $9.86. The firm has a market capitalization of $259.38 million, a P/E ratio of -5.09 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.21. The company had revenue of $0.08 million for the quarter. As a group, sell-side analysts predict that Actinium Pharmaceuticals will post -1.48 earnings per share for the current fiscal year.

Institutional Trading of Actinium Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Brandywine Global Investment Management LLC bought a new stake in Actinium Pharmaceuticals in the 3rd quarter valued at approximately $1,033,000. Creative Financial Designs Inc. ADV lifted its position in shares of Actinium Pharmaceuticals by 19.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 3,175 shares in the last quarter. Finally, Sanders Morris Harris LLC bought a new position in Actinium Pharmaceuticals in the first quarter valued at $78,000. 27.50% of the stock is owned by institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.